Deciphera Pharmaceuticals (DCPH) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research lowered shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) from a buy rating to a hold rating in a research report sent to investors on Monday.

According to Zacks, “Deciphera Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib which are in clinical stage. Deciphera Pharmaceuticals, LLC is based in WALTHAM, United States. “

Several other research firms have also commented on DCPH. BidaskClub raised Deciphera Pharmaceuticals from a sell rating to a hold rating in a report on Wednesday, January 3rd. Nomura assumed coverage on Deciphera Pharmaceuticals in a report on Monday, October 23rd. They set a buy rating and a $57.00 price objective on the stock. Piper Jaffray Companies assumed coverage on Deciphera Pharmaceuticals in a report on Monday, October 23rd. They set an overweight rating and a $35.00 price objective on the stock. Instinet assumed coverage on Deciphera Pharmaceuticals in a report on Monday, October 23rd. They set a buy rating and a $57.00 price objective on the stock. Finally, JMP Securities assumed coverage on Deciphera Pharmaceuticals in a report on Monday, October 23rd. They set an outperform rating and a $38.00 price objective on the stock. Seven equities research analysts have rated the stock with a buy rating, The stock presently has an average rating of Buy and a consensus price target of $40.83.

Deciphera Pharmaceuticals (NASDAQ:DCPH) traded up $0.59 during trading hours on Monday, reaching $25.66. The company had a trading volume of 134,500 shares, compared to its average volume of 185,686. The stock has a market capitalization of $815.93 and a price-to-earnings ratio of -6.48. Deciphera Pharmaceuticals has a 52-week low of $15.15 and a 52-week high of $26.59.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its earnings results on Tuesday, November 14th. The company reported ($5.85) EPS for the quarter, missing the consensus estimate of ($0.55) by ($5.30). equities research analysts forecast that Deciphera Pharmaceuticals will post -2.91 EPS for the current fiscal year.

Hedge funds have recently modified their holdings of the business. SG Americas Securities LLC purchased a new position in shares of Deciphera Pharmaceuticals during the third quarter worth about $143,000. FNY Managed Accounts LLC purchased a new position in shares of Deciphera Pharmaceuticals during the third quarter worth about $153,000. Pura Vida Investments LLC purchased a new position in shares of Deciphera Pharmaceuticals during the third quarter worth about $1,329,000. Sphera Funds Management LTD. purchased a new position in shares of Deciphera Pharmaceuticals during the third quarter worth about $1,424,000. Finally, Perceptive Advisors LLC purchased a new position in shares of Deciphera Pharmaceuticals during the third quarter worth about $1,946,000. 43.94% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was posted by Markets Daily and is the sole property of of Markets Daily. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.themarketsdaily.com/2018/01/11/deciphera-pharmaceuticals-dcph-stock-rating-lowered-by-zacks-investment-research.html.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases.

Get a free copy of the Zacks research report on Deciphera Pharmaceuticals (DCPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply